PET-MRI combination may change management of high-risk cancer patients

PET/CT and whole-body MRI detect extraskeletal disease that may change the management of high-risk breast and prostate cancer patients, according to a recent study reported in The Journal of Nuclear Medicine. In addition, the combined administration of F-18 sodium fluoride (NaF) and F-18 fluorodeoxyglucose (FDG) in a single PET/CT scan showed significantly higher sensitivity and accuracy than alternative methods for the detection of skeletal lesions. Read more.